Congenital heart disease-associated pulmonary arterial hypertension: Preliminary results from a novel registry

Internal Medicine Journal

Volumn 42, Issue 8, 2012, Pages 874-879

  Rose, M L ^a,b   Strange, G ^c,f   King, I ^a,b   Arnup, S ^b,d   Vidmar, S ^b,d   O'Donnell, C ⁱ   Kermeen, F ^h   Grigg, L ^e   Weintraub, R G ^a,b   Celermajer, D S ^f,g  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h THE PRINCE CHARLES HOSPITAL   (Australia)

ⁱ STARSHIP CHILDREN S HOSPITAL   (New Zealand)

Author keywords

Congenital heart disease; Eisenmenger syndrome; Pulmonary arterial hypertension; Registry

Indexed keywords

ANTICOAGULANT AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR;

ADULT; ARTICLE; AUSTRALIA AND NEW ZEALAND; CLINICAL FEATURE; CONGENITAL HEART DISEASE; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOWN SYNDROME; ECHOCARDIOGRAPHY; EISENMENGER COMPLEX; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HUMAN; INCIDENCE; INTERNET; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; REGISTER; SYSTEMIC PULMONARY SHUNT;

ADULT; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MALE; PROSPECTIVE STUDIES; REGISTRIES; YOUNG ADULT;

EID: 84865368483     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02708.x     Document Type: Article

References (18)

1. Heartkids. Available from URL: http://heartkids.org.au/support-for-families/facts-about-chd/
2. van der Velde ET, Vriend JWJ, Mannens MMAM, Uiterwaal CSPM, Brand R, Mulder BJM. Concor, an initiative towards a national registry and DNA-bank of patients with congenital heart disease in the Netherlands: rationale, design, and first results [Published erratum appears in Eur J Epidemiol 2005; 20: 885]. Eur J Epidemiol 2005; 20: 549-57.
3. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115: 163-72.
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G etal. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
5. Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, O'Fallon WM etal. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993; 87: I38-51.
6. Hoffman JI. Natural history of congenital heart disease. Problems in its assessment with special reference to ventricular septal defects. Circulation 1968; 37: 97-125.
7. Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995; 16: 103-13.
8. Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58: 538-46.
9. Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RLE, Hoendermis E, Vriend JWJ etal. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a dutch registry. Int J Cardiol 2007; 120: 198-204.
10. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A etal. Bosentan randomized trial of endothelin antagonist therapy I. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
11. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA etal. Guidelines ESCCfP. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [Published erratum appears in Eur Heart J 2011; 32: 926]. Eur Heart J 2011; 30: 2493-537.
12. Evans SM, Bohensky M, Cameron PA, McNeil J. A survey of australian clinical registries: can quality of care be measured? Intern Med J 2011; 41: 42-8.
13. Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S etal. The Bosentan patient registry: long-term survival in pulmonary arterial hypertension. Intern Med J 2011; 41: 227-34.
14. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V etal. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30.
15. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS etal. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-72.
16. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-9.
17. Van de Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R etal. The Belgian Eisenmenger syndrome registry: implications for treatment strategies? Acta Cardiol 2009; 64: 447-53.
18. Engelfriet P, Boersma E, Oechslin E, Tijssen J, Gatzoulis MA, Thilen U etal. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26: 2325-33.